2022 has been rough for many previous market darlings. Investors have moved to higher ground, deserting growth stocks in exchange for large, stable companies. However, savvy healthcare investors should treat this pullback as a buying opportunity. We'll look at two healthcare stocks that could go parabolic thanks to continued, strong growth.

Maker of genetic testing kits for a multitude of rare diseases across multiple medical specialties -- from ophthalmology to nephrology, and most organ systems in between -- Invitae (NYSE: NVTA) has been hit hard lately. And while some of that can be attributed to dilution, its ramping revenue should squash those concerns.

Invitae has ridden the personalized medicine wave and is firing on all cylinders. Fiscal 2021 revenue for its four core service lines have all roughly doubled over 2019 numbers.

Continue reading

Source Fool.com